About the job
The Director of HEOR Strategy for the Immunology Pipeline is responsible for spearheading the integrated Health Economics and Outcomes Research (HEOR) evidence strategy for our dermatology and select rheumatology pipeline assets. This leader will ensure that evidence plans are aligned with cross-functional asset strategies to facilitate the advancement of pipeline assets through all phases of development (Phase 1 to Phase 3). By driving clinical outcomes assessment strategies, the Director will secure essential label-enabling endpoints, generate substantial real-world evidence to inform asset development, and guide economic value assessments to support global access and reimbursement initiatives.
The ideal candidate will showcase exceptional cross-functional leadership skills, influencing HEOR strategies across matrix teams to create compelling product value propositions that yield significant impact. The Director will also utilize their expertise to craft evidence roadmaps that shape long-term strategies in disease areas and amplify the future impact of our portfolio.
This position can be based in any of the following locations within the United States: Lake County, IL; Cambridge, MA; Irvine, CA; or Florham Park, NJ.
Key Responsibilities
- Lead the HEOR strategy by developing a comprehensive evidence strategy for immunology (including rheumatology and dermatology) assets, ensuring alignment with asset differentiation, labeling, and global access goals throughout all development phases.
- Facilitate matrix decision-making via the Pipeline Commercialization Model (PCM), collaborating with clinical development, medical, regulatory, market access, and commercial teams to navigate trade-offs and promote timely, evidence-based decisions.
- Direct the Clinical Outcomes Assessment (COA) strategy by selecting, validating, and implementing Patient-Reported Outcomes (PROs) and COAs in clinical trials, engaging with regulators on endpoint acceptability, and pursuing label-enabling claims and differentiation.
- Drive the generation of real-world evidence (RWE) to inform trial design, target populations, unmet treatment needs, disease burden, patient journeys, and the future value of assets across various stakeholders.
- Oversee economic value assessments, including cost-effectiveness, budget impact, pricing scenarios, and health-state utilities, to clearly define product value, support pricing and reimbursement strategies, and shape asset value narratives.
- Provide leadership in creating integrated value propositions, establishing value frameworks and narratives, and conducting affiliate engagements to influence asset strategy and evidence generation plans to meet global stakeholder requirements.
- In collaboration with market access, lead the development of global value dossiers, health technology assessment (HTA) strategies, access evidence gap closure plans, scenario analyses, and advisory engagements to proactively address payer requirements.
- Shape therapeutic area strategies by identifying and developing compelling evidence and novel endpoints to anticipate future asset value demonstration needs.